Next Generation ECG Monitoring System E!5274

Novosense patented technology represents a new way of measuring ECGs. The proposed ECG monitoring system is intended to replace today's stationary and portable equipment. The Sensor measures ECG with Novosenses patented measurement technology, is totally self-contained and relies on wireless communication to transmit the patent data. The measuring technology makes it possible to monitor ECG without any cables on the body, which is unique and there exist today no similar ECG monitoring system. ECG signals would then be transmitted via a radio to a Base Station connected to the local network and where the signals are relayed to the Back-End System. The ECG information is integrated to the hospitals clinical information systems via the Back-End System and co uld thus be saved or analysed using existing installed systems. The Base Station would also be able to transmit ECG data to a bedside monitor providing a smaller solution where this is suitable. ntegrating Noveldas Ultra Wideband Impulse Radio (UWB-IR) t echnology with Novosense ECG technology would deliver several benefits. The radio technology has a very low power consumption, which would increase the ECG sensors operational life span. The radio technology is designed to apply with worldwide standards d efining the range of allowable/available frequencies (FCC: 3.1GHz to 10.6GHz, ETSI: 6.0GHz to 8.5GHz). Thus the ECG sensor system could be marketed world wide. The high bandwidth allows for disturbance free coexistence of several transceivers and thus sup ports many sensors at a high data rate operating in close vicinity. Furthermore the UWB-band is today unoccupied as there are basically no products on the market utilising the UWB frequencies. Taking the high bandwidth, the low frequency utilisation and t he appliance to worldwide standards into account, the Novelda radio solution would give Novosense ECG system a significant advantage compared to competing telemetry systems.